Clinical Outcomes and Costs Analyses in Use of Goal Directed Therapy
Not Applicable
Completed
- Conditions
- Postoperative Complications
- Interventions
- Device: Goal Directed Fluid Therapy FloTrac/Vigileo
- Registration Number
- NCT01995786
- Lead Sponsor
- Regina Elena Cancer Institute
- Brief Summary
The aim of the study is to evaluate clinical and economic impact of Goal Directed Fluid Therapy according to NICE haemodynamic protocol. Haemodynamic parameters were assessed using automated pulse contour analysis (Flotrac/Vigileo®). A specific dedicated software has been developed to perform clinical and expenditures data collection, both retrospective and prospective data are archived.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Patients selected for major abdominal surgery
Exclusion Criteria
•Patients under the age of 18, patients with hemodynamically significant aortic regurgitation and heart rhythm disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description GDT Goal Directed Fluid Therapy FloTrac/Vigileo Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 2,5 ml/kg/h and boluses of crystalloids for values of stroke volume (SV) \< SV TRIGGER. Every additional infusion of colloids, blood derivates, drugs must be recorded
- Primary Outcome Measures
Name Time Method rate of reduction of postoperative spending 30 day postoperative
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Regina Elena CI
🇮🇹Rome, Italy